List of Zimhi drug patents
Zimhi is owned by Adamis Pharms Corp.
Zimhi contains Naloxone Hydrochloride.
Zimhi has a total of 2 drug patents out of which 0 drug patents have expired.
Zimhi was authorised for market use on 15 October, 2021.
Zimhi is available in solution;intramuscular, subcutaneous dosage forms.
Zimhi can be used as a method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; a method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a needle guard; a method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device including a window configured to allow the user to view the opioid antagonist in the syringe.
The generics of Zimhi are possible to be released after 14 June, 2041.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11027072 | ADAMIS PHARMS CORP | Emergency devices |
May, 2039
(15 years from now) | |
| US11571518 | ADAMIS PHARMS CORP | NA |
Jun, 2041
(18 years from now) | |
Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient
Market Authorisation Date: 15 October, 2021
Treatment: A method for administering a therapeutic dose of an opioid antagonist comprising an emergency syringe device; A method for administering a therapeutic dose of an opioid antagonist comprising an emerge...
Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS
ZIMHI family patents
6
United States
1
Korea, Republic of
1
China
1
Israel
1
Canada
1
Japan
1
Australia
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic